

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claims:**

1. (original) A formulation comprising one or more gangliosides selected from the group consisting of GD3, GM2, GM3, GD1b, NANA, and sialic acid, for mediating inflammation.
2. (original) The formulation of claim 1, comprising the ganglioside GD3.
3. (currently amended) The formulation of claim 1 ~~or 2~~, comprising the ganglioside GM3.
4. (currently amended) The formulation of ~~any one of claims 1 to 3~~ claim 1, wherein the percentage of GD3 as a function of total gangliosides is at least 50% by weight.
5. (currently amended) The formulation of ~~any one of claims 1 to 3~~ claim 1, wherein the percentage of GM3 as a function of total gangliosides is at least 50% by weight.
6. (original) The formulation of claim 1, comprising 70-90% GD3 and 0-15% GM3 by weight based on total gangliosides.
7. (original) The formulation of claim 1 comprising about 80% GD3 and about 5% GM3 by weight based on total gangliosides.
8. (currently amended) The formulation of ~~any one of claims 1 to 7~~ claim 1, wherein mediating inflammation comprises mediating inflammation of the intestine, retina, or neuronal tissue.

9. (currently amended) The formulation of ~~any one of claims 1 to 8~~ claim 1, wherein mediating inflammation comprises preventing or treating an inflammatory disease.
10. (original) The formulation of claim 9, wherein said inflammatory disease is selected from the group consisting of inflammatory bowel disorders, disorders arising from allergic responses, and diseases involving epithelial surface responses.
11. (currently amended) The formulation of ~~any one of claims 1 to 10~~ claim 1, in the form of a supplemented liquid or food.
12. (original) The formulation of claim 11, wherein said supplemented liquid or food comprises infant formula or infant foods.
13. (currently amended) A method for mediating inflammation in a subject in need thereof comprising the step of providing the formulation of ~~any one of claims 1 to 12~~ claim 1 to said subject for oral consumption.
14. (canceled)
15. (canceled)
16. (original) A formulation comprising one or more gangliosides selected from the group consisting of GD3, GM2, GM3, GD1b, NANA, and sialic acid, for reducing plasma cholesterol level.
17. (currently amended) The formulation of claim 16, comprising the ganglioside GD3 or GM3.
18. (canceled)

19. (currently amended) The formulation of ~~any one of claims 16 to 18~~ claim 16, wherein the percentage of GD3 as a function of total gangliosides is at least 50% by weight.
20. (currently amended) The formulation of ~~any one of claims 16 to 18~~ claim 16, wherein the percentage of GM3 as a function of total gangliosides is at least 50% by weight.
21. (original) The formulation of claim 16, comprising 70-90% GD3 and 0-15% GM3 by weight based on total gangliosides.
22. (original) The formulation of claim 16, comprising about 80% GD3 and about 5% GM3 by weight based on total gangliosides.
23. (currently amended) The formulation of ~~any one of claims 16 to 22~~ claim 16, in the form of a supplemented liquid or food.
24. (original) The formulation of claim 23, wherein said supplemented liquid or food comprises infant formula or infant foods.
25. (currently amended) A method for reducing plasma cholesterol level in a subject in need thereof comprising the step of providing the formulation of ~~any one of claims 16-24~~ claim 16 to said subject for oral consumption.
26. (canceled)
27. (canceled)